Published in Nat Rev Urol on March 31, 2016
Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosis. BMJ Open (2017) 0.75
Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. Urol Clin North Am (2017) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn (2010) 4.48
Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain (1980) 3.27
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol (2005) 2.68
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol (2011) 2.37
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol (2012) 2.25
Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol (2006) 2.19
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler (2004) 2.15
Effect of bladder management on urological complications in spinal cord injured patients. J Urol (2000) 1.88
Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol (2010) 1.67
Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol (2007) 1.66
Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. Urology (2008) 1.65
Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis--a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn (2008) 1.63
Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol (2007) 1.60
Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology (2013) 1.52
Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol (2007) 1.45
Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil (1998) 1.42
Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology (1999) 1.40
Long-term follow-up of transvaginal urethral closure and suprapubic cystostomy for urinary incontinence in women with multiple sclerosis. Br J Urol (1994) 1.39
[Pelvic floor rehabilitation for female urinary incontinence: mechanisms of action]. Prog Urol (2013) 1.39
[A technique of continent vesicostomy with ileocystoplasty: study of 32 patients]. Prog Urol (2008) 1.38
The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler (2007) 1.38
Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol (2001) 1.36
What drives quality of life in multiple sclerosis? QJM (2004) 1.33
Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol (1999) 1.32
Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler (2007) 1.27
Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol (2011) 1.23
Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry (1993) 1.20
A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry (2009) 1.19
Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology (2007) 1.18
Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol (2001) 1.18
Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol (1995) 1.17
Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol (2015) 1.17
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol (2008) 1.16
The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med (1994) 1.12
Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol (1995) 1.11
Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn (2006) 1.11
The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.10
Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn (2011) 1.08
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol (2007) 1.07
Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol (2007) 1.07
Caffeine reduction education to improve urinary symptoms. Br J Nurs (2002) 1.05
Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol (2000) 1.05
Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol (2010) 1.05
Long-term results of augmentation cystoplasty. Eur Urol (1998) 1.03
Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology (2001) 1.03
Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. Urology (1997) 1.02
Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer Adherence (2014) 1.01
Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci (2015) 1.00
Is suprapubic cystostomy an optimal urinary management in high quadriplegics?. A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol (2000) 0.99
Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol Urodyn (2011) 0.98
Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler (2008) 0.97
Reappraisal of endoscopic sphincterotomy for post-traumatic neurogenic bladder: a prospective study. J Urol (1996) 0.97
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler (2010) 0.97
Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev (2009) 0.96
Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol (1986) 0.96
Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med (2004) 0.95
Urodynamic pattern changes in multiple sclerosis. Urology (2001) 0.94
Neuromodulation of the lower urinary tract. Exp Physiol (1999) 0.92
Lower urinary tract dysfunction in multiple sclerosis. Urology (1992) 0.91
Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil (1997) 0.90
Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg (1999) 0.89
Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn (2009) 0.89
Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol (1998) 0.89
Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn (1998) 0.89
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2005) 0.88
Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil (1999) 0.88
The Mitrofanoff procedure: 20 years later. J Urol (2001) 0.88
Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol (2003) 0.87
The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol (2010) 0.86
Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn (2006) 0.86
Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol (2002) 0.85
The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry (1983) 0.85
Transcutaneous posterior tibial nerve stimulation for treatment of detrusor hyperreflexia in spinal cord injury. J Urol (2003) 0.85
The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn (2009) 0.84
Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report. Neurourol Urodyn (2013) 0.84
Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil (2009) 0.84
Robotic enterocystoplasty: technique and early outcomes. J Endourol (2010) 0.83
Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn (2014) 0.83
Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch Phys Med Rehabil (1995) 0.83
Urinary diversion and orthotopic bladder substitution in children and young adults with neurogenic bladder: a safe option for treatment? J Urol (2000) 0.82
[Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases]. Rev Neurol (Paris) (1995) 0.82
Clean, intermittent self-catheterization in the treatment of urinary tract disease. Trans Am Assoc Genitourin Surg (1971) 0.82
Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J (2009) 0.82
The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis. Mult Scler (2014) 0.81
Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report. Neuromodulation (2005) 0.81
Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol (1996) 0.81
Prevalence of stress urinary incontinence in women with multiple sclerosis. Int Neurourol J (2012) 0.81
Sacral neuromodulation in patients with multiple sclerosis. World J Urol (2011) 0.81
The value of the Kurtzke Functional Systems Scales in predicting incomplete bladder emptying. Spinal Cord (2000) 0.81
Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler (2008) 0.80
Biofeedback treatment of bladder dysfunction in multiple sclerosis. A randomized trial. Scand J Urol Nephrol Suppl (1994) 0.80
Conservative bladder management in advanced multiple sclerosis. Mult Scler (2005) 0.80
Prognostic factors for successful percutaneous tibial nerve stimulation. Eur Urol (2005) 0.80
Correlation of urinalysis and dipstick results with catheter-associated urinary tract infections in surgical ICU patients. Intensive Care Med (2006) 0.80
Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand (2005) 0.80